The present invention provides a screening method for a cancer therapeutic material using cyclin B1 (Cyclin B1), cyclin-dependent kinase 1 (Cyclin-dependent kinase 1; CDK1), and retinoic acid receptor responder 1 (RARRES1), And as a composition for cancer diagnosis or prognosis prediction, the present inventors intensively studied to find out the molecular mechanism for cancer diagnosis and prognosis prediction. As a result, according to the degree of mutual binding of RARRES1 and CDK1 or Cyclin B1 in cancer-derived subjects, It was confirmed that RARRES1 is an important factor in cancer diagnosis, prognosis, and treatment by confirming that it inhibits the mitosis of cancer cells, inhibits the formation of the CDK1-Cyclin B1 complex, and promotes the degradation of these proteins. The degree of binding of RARRES1 is reduced, the degree of binding of the RARRES1 to CDK1 or Cyclin B1 is increased, and the stability or activity of the CDK1 or Cyclin B1 protein is reduced. It is expected that there will be
展开▼
